AbCellera Biologics (ABCL) Revenue (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Revenue data on file, last reported at $8.3 million in Q1 2026.

• Quarterly Revenue rose 96.34% year-over-year to $8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.2 million (up 242.66% YoY) and the FY2025 annual result came in at $75.1 million, up 160.56% from the prior year.
• Revenue eased to $8.3 million in Q1 2026, from $44.9 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $316.6 million in Q1 2022 to a low of $4.2 million in Q1 2025.
• A 5-year average of $37.4 million and a median of $10.0 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue surged 1740.65% — and 2023, when it plunged 96.15%.
• Tracing ABCL's Revenue over 5 years: stood at $21.5 million in 2022, then tumbled by 57.4% to $9.2 million in 2023, then sank by 44.98% to $5.0 million in 2024, then jumped by 788.18% to $44.9 million in 2025, then plunged by 81.46% to $8.3 million in 2026.
• The last three Revenue figures came in at $8.3 million (Q1 2026), $44.9 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.